EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial)

Tatiana Mögele, Michael Höck, Florian Sommer iD, Lena Friedrich, Sebastian Sommer, Maximilian Schmutz iD, Amadeus Altenburger, Helmut Messmann, Matthias Anthuber, Thomas Kröncke iD, Georg Stüben, Martin Trepel und 3 weitere

Cancers · 14.12.2024 · 16 (24) · 4173

DOI: 10.3390/cancers16244173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 14.12.2024. Verfasst von Tatiana Mögele und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pathology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Förderkreis des Tumorzentrums Augsburg e.V..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Locally advanced rectal cancer is treated with neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). As this approach achieves complete pathologic remissions (pCR) in approximately 30% of patients, it raises the question of whether surgery is always necessary. Non-surgical strategies, such as “watch and wait” (W&W), have shown similarly promising outcomes. However, there is an unmet need for reliable biomarkers predicting pCR. Analysis of circulating tumor DNA (ctDNA) has shown potential for monitoring treatment response and detecting minimal residual disease. We hypothesized that monitoring ctDNA changes during nCRT might facilitate the identification of individuals who achieve pCR.

Methods

In the prospective single-center NEORECT trial, the plasma of forty rectal cancer patients was collected before, during, and after nCRT and before TME. Informative somatic mutations were identified in tissue biopsies by NGS and subsequently used for ctDNA quantification by dPCR.

Results

The results identified three distinct ctDNA patterns: increase, decrease, and absence. Remarkably, undetectable DNA was observed in good responders, while a tenfold ctDNA increase was associated with the emergence of new metastases. Despite these insights, ctDNA alone demonstrated low specificity, with no significant correlation to pCR or long-term prognosis. A multimodal approach incorporating routinely available clinical parameters remains inadequate for accurately predicting pCR prior to TME.

Conclusions

In conclusion, the NEORECT trial establishes the feasibility of ctDNA-based personalized monitoring for rectal cancer patients undergoing nCRT. However, the utility of ctDNA in enhancing pCR prediction for a W&W strategy warrants further investigation. Larger studies integrating multi-gene analyses and expanded clinical datasets are essential in the future.

Schlagwörter

Stichwörter der Autor:innen

circulating tumor DNAcomplete pathological responseneoadjuvant radiochemotherapyrectal cancerresponse prediction

Autor:innen und Institutionen

  • Pathology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Bavarian Cancer Research Center (BZKF), Germany.
  • Radiotherapy, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • General and Visceral Surgery, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Diagnostic and Interventional Neuroradiology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
  • Hematology and Oncology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.

ORCID-Profile: Florian Sommer, Maximilian Schmutz, Thomas Kröncke, Sebastian Dintner, Rainer Claus

Förderung

  • Förderkreis des Tumorzentrums Augsburg e.V.

Zitieren

APA

Mögele, T., Höck, M., Sommer, F., Friedrich, L., Sommer, S., Schmutz, M., Altenburger, A., Messmann, H., Anthuber, M., Kröncke, T., Stüben, G., Trepel, M., Märkl, B., Dintner, S., & Claus, R. (2024). Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial). Cancers, 16(24), 4173. https://doi.org/10.3390/cancers16244173

Vancouver

Mögele T, Höck M, Sommer F, Friedrich L, Sommer S, Schmutz M, et al. Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial). Cancers. 2024;16(24):4173. doi:10.3390/cancers16244173

BibTeX
@article{Mgele2024,
  author = {Mögele, Tatiana and Höck, Michael and Sommer, Florian and Friedrich, Lena and Sommer, Sebastian and Schmutz, Maximilian and Altenburger, Amadeus and Messmann, Helmut and Anthuber, Matthias and Kröncke, Thomas and Stüben, Georg and Trepel, Martin and Märkl, Bruno and Dintner, Sebastian and Claus, Rainer},
  title = {Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial)},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {24},
  pages = {4173},
  doi = {10.3390/cancers16244173}
}
Kostenlos starten →